The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...

Breo Ellipta inhaler cleared for long-term use Breo Ellipta delivers a combination of two drugs Drug not approved for asthma treatment WASHINGTON (AP) — The Food and Drug Administration says it has ...

LONDON—A large clinical trial run by GlaxoSmithKline PLCGSK1.12%increase; green up pointing triangle has failed to show that the company’s Breo Ellipta inhaler extends life in patients with chronic ...

At first blush, the pedestrian world of drug manufacturing and the high-speed environs of Formula One racing would seem to have little in common. But GlaxoSmithKline ...